Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Myr GmbH is active in the Biotechnology & Pharmaceuticals technology area, where it currently faces 1 pending office action. This action is under the review of 1 distinct examiner, suggesting a streamlined approach to its current patent filings. The company's work is situated within 1 distinct art unit, which provides a stable regulatory framework for its intellectual property development.
The busiest examiner, FISCHER, JOSEPH, is managing the 1 busiest examiner pending action for the company. Since there is only 1 distinct examiner, the company's prosecution strategy is entirely focused on meeting the specific expectations of this individual. This concentration simplifies the management of the portfolio, as there are no other examiners or art units to coordinate with at this time.
With 1 pending office action, the company's current engagement with the USPTO is limited in scale. The Biotechnology & Pharmaceuticals sector can be broad, but the use of 1 distinct art unit indicates a specific technical niche. Practitioners can dedicate their resources to addressing the concerns raised in the 1 pending office action, knowing that FISCHER, JOSEPH is the sole arbiter for this current stage of prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17209615 | COMBINATION THERAPY OF HBV AND HDV INFECTION | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17209615 | COMBINATION THERAPY OF HBV AND HDV INFECTION | FISCHER, JOSEPH | 1658 | §103 | Non-Final OA | — | Pending | Mar 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial